{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:57:02Z","timestamp":1781157422897,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01847-0","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:37:55Z","timestamp":1781149075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paclitaxel prodrug loaded high-density lipoprotein nanoparticles for chemoimmunotherapy of triple-negative breast cancer"],"prefix":"10.1038","author":[{"given":"Lin-yang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-ru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qiang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1847_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, Savas P, Virassamy B, O\u2019Malley MMR, Kay J, Mueller SN, et al. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24:554\u201377.","journal-title":"Nat Rev Cancer"},{"key":"1847_CR2","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997\u20134013.","journal-title":"J Clin Oncol"},{"key":"1847_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"1847_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16:100.","journal-title":"J Hematol Oncol"},{"key":"1847_CR5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple-negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15:1796.","journal-title":"Pharmaceutics"},{"key":"1847_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s43556-022-00071-6","volume":"3","author":"R Yang","year":"2022","unstructured":"Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed. 2022;3:8.","journal-title":"Mol Biomed"},{"key":"1847_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660\u201370.","journal-title":"Nat Immunol"},{"key":"1847_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","volume":"20","author":"G Mountzios","year":"2023","unstructured":"Mountzios G, Remon J, Hendriks LEL, Garc\u00eda-Campelo R, Rolfo C, Van Schil P, et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023;20:664\u20137.","journal-title":"Nat Rev Clin Oncol"},{"key":"1847_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184.","journal-title":"J Immunother Cancer"},{"key":"1847_CR10","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41590-024-02015-4","volume":"25","author":"S Goswami","year":"2024","unstructured":"Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024;25:2186\u201399.","journal-title":"Nat Immunol"},{"key":"1847_CR11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"1847_CR12","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1002\/mco2.551","volume":"5","author":"S Qin","year":"2024","unstructured":"Qin S, Xie B, Wang Q, Yang R, Sun J, Hu C, et al. New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication. MedComm. 2024;5:e551.","journal-title":"MedComm"},{"key":"1847_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345\u201359.","journal-title":"Nat Rev Cancer"},{"key":"1847_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1126\/science.271.5248.518","volume":"271","author":"S Acton","year":"1996","unstructured":"Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518\u201320.","journal-title":"Science"},{"key":"1847_CR15","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u201378.","journal-title":"N Engl J Med"},{"key":"1847_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1847_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"1847_CR18","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394.","journal-title":"J Clin Oncol"},{"key":"1847_CR19","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"1847_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1847_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med"},{"key":"1847_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.","journal-title":"J Hematol Oncol"},{"key":"1847_CR23","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"1847_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity. 2018;49:178\u201393.e7.","journal-title":"Immunity"},{"key":"1847_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"1847_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","volume":"22","author":"E Catanzaro","year":"2025","unstructured":"Catanzaro E, Beltr\u00e1n-Visiedo M, Galluzzi L, Krysko DV. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol Immunol. 2025;22:24\u201339.","journal-title":"Cell Mol Immunol"},{"key":"1847_CR27","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016;8:370ra180.","journal-title":"Sci Transl Med"},{"key":"1847_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15\u201325.","journal-title":"Cell Death Differ"},{"key":"1847_CR29","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578\u201393.","journal-title":"Cancer Cell"},{"key":"1847_CR30","doi-asserted-by":"publisher","first-page":"102026","DOI":"10.1016\/j.nantod.2023.102026","volume":"53","author":"AO Elzoghby","year":"2023","unstructured":"Elzoghby AO, Samir O, Soliman A, Solomevich S, Yu M, Schwendeman A, et al. Nanodiscs: game changer nano-therapeutics and structural biology tools. Nano Today. 2023;53:102026.","journal-title":"Nano Today"},{"key":"1847_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.humpath.2003.08.015","volume":"35","author":"MI Arenas","year":"2004","unstructured":"Arenas MI, Lobo MVT, Caso E, Huerta L, Paniagua R, Mart\u0131\u0301n-Hidalgo MA. Normal and pathological human testes express hormone-sensitive lipase and the lipid receptors CLA-1\/SR-BI and CD36. Hum Pathol. 2004;35:34\u201342.","journal-title":"Hum Pathol"},{"key":"1847_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489\u201396.","journal-title":"Nat Mater"},{"key":"1847_CR33","doi-asserted-by":"publisher","first-page":"e06011","DOI":"10.1002\/adma.202506011","volume":"37","author":"K Shang","year":"2025","unstructured":"Shang K, Tang D, Cui M, Hou H, Xiao B, Liu J, et al. Synthetic high-density lipoprotein mimicking nanodiscs with Pt(IV) prodrug enable tumor targeting and cGAS-STING pathway activation for chemo-immunotherapy. Adv Mater. 2025;37:e06011.","journal-title":"Adv Mater"},{"key":"1847_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrd4279","volume":"13","author":"BA Kingwell","year":"2014","unstructured":"Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014;13:445\u201364.","journal-title":"Nat Rev Drug Discov"},{"key":"1847_CR35","doi-asserted-by":"publisher","first-page":"eadk9996","DOI":"10.1126\/sciadv.adk9996","volume":"10","author":"C Zheng","year":"2024","unstructured":"Zheng C, Zhang W, Gong X, Xiong F, Jiang L, Zhou L, et al. Chemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles. Sci Adv. 2024;10:eadk9996.","journal-title":"Sci Adv"},{"key":"1847_CR36","doi-asserted-by":"publisher","first-page":"159068","DOI":"10.1016\/j.bbalip.2021.159068","volume":"1867","author":"A Ossoli","year":"2022","unstructured":"Ossoli A, Wolska A, Remaley AT, Gomaraschi M. High-density lipoproteins: a promising tool against cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867:159068.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"1847_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jconrel.2024.01.064","volume":"367","author":"X Gong","year":"2024","unstructured":"Gong X, Zheng C, Cai Y, Zhang W, Zhu B, Rong R, et al. Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer. J Control Release. 2024;367:637\u201348.","journal-title":"J Control Release"},{"key":"1847_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2019.12.025","volume":"80","author":"D Wang","year":"2022","unstructured":"Wang D, Huang J, Gui T, Yang Y, Feng T, Tzvetkov NT, et al. SR-BI as a target of natural products and its significance in cancer. Semin Cancer Biol. 2022;80:18\u201338.","journal-title":"Semin Cancer Biol"},{"key":"1847_CR39","doi-asserted-by":"publisher","first-page":"e2306676","DOI":"10.1002\/adma.202306676","volume":"36","author":"Y Cai","year":"2024","unstructured":"Cai Y, Zhu B, Shan X, Zhou L, Sun X, Xia A, et al. Inhibiting endothelial cell-mediated T lymphocyte apoptosis with integrin-targeting peptide-drug conjugate filaments for chemoimmunotherapy of triple-negative breast cancer. Adv Mater. 2024;36:e2306676.","journal-title":"Adv Mater"},{"key":"1847_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2023.12.015","volume":"187","author":"Z Li","year":"2024","unstructured":"Li Z, Ma R, Tang H, Guo J, Shah Z, Zhang J, et al. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell. 2024;187:624\u201341.","journal-title":"Cell"},{"key":"1847_CR41","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","volume":"35","author":"L Wu","year":"2023","unstructured":"Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, et al. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1. Cell Metab. 2023;35:1580\u201396.","journal-title":"Cell Metab"},{"key":"1847_CR42","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49:1148\u201361.e7.","journal-title":"Immunity"},{"key":"1847_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","volume":"50","author":"ED Tait Wojno","year":"2019","unstructured":"Tait Wojno ED, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019;50:851\u201370.","journal-title":"Immunity"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01847-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:02:15Z","timestamp":1781154135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01847-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":43,"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01847-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Qing-min Yang and Ming-hui Zhang are employees of Qilu Pharmaceutical Co. Ltd. Yan-qiang Shan is an employee of Qilu Pharmaceutical (Hainan) Co. Ltd. Han-zhi Li is an employee of Hongliang (Shanghai) Biopharmaceutical Technology Co. Ltd. These employment relationships had no influence on the study design, data collection and analysis, interpretation of results, manuscript preparation, or decision to publish. All authors declare that there is no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}